Quarterly ResultMay 11, 2026, 06:33 AM
Liquidia Q1 Net Income $52.9M; YUTREPIA Sales $130M
AI Summary
Liquidia Corporation reported strong financial results for the first quarter ended March 31, 2026, marking its third consecutive quarter of profitability. The company achieved net income of $52.9 million and adjusted EBITDA of $71.2 million, driven by YUTREPIA net product sales of approximately $130 million. Liquidia also saw significant commercial uptake for YUTREPIA, with over 4,500 unique patient prescriptions and 3,750 patients treated since its June 2025 launch, and initiated new Phase 4 and Phase 3 clinical studies.
Key Highlights
- Q1 2026 net income was $52.9 million, compared to a net loss of $38.4 million in Q1 2025.
- Adjusted EBITDA reached $71.2 million in Q1 2026, up from $27.3 million in Q4 2025.
- YUTREPIA net product sales were $129.9 million in Q1 2026.
- Cash and cash equivalents increased to $222.8 million as of March 31, 2026.
- Over 4,500 unique patient prescriptions for YUTREPIA since June 2025 launch.
- Approximately 3,750 patients treated with YUTREPIA since June 2025 launch.
- R&D expenses increased by $5.6 million to $12.6 million in Q1 2026.
- Pivotal Phase 3 Re-Spire study of L606 has been initiated.